Ranbaxy may have to pay huge fine, again
Ranbaxy Laboratories, set to be merged with Sun Pharmaceutical Industries, might again have to pay a hefty penalty to the US authorities for alleged violations at its Toansa factory in Punjab. The facility
Ranbaxy Pharmaceuticals
-
Policy reforms in the Indian pharmaceutical sector since 1994 - Impact on exports and imports
Liberalisation measures in the pharmaceutical sector have brought about major changes in the industrial licensing policy, import restrictions, foreign direct investment and production controls. It was
-
Native anti-malaria drug launched
India on Wednesday launched its first indigenously manufactured anti-malaria new-age drug Synriam. The drug, produced by Ranbaxy Laboratories, was formally introduced for marketing here. The drug, launched by Health Minister Ghulam Nabi Azad in the presence of Science and Technology Minister Vilasrao Deshmukh, has been developed by the company in collaboration with the Department of Science and Technology and supported by the Indian Council for Medical Research.
-
Now, a synthetic anti-malaria drug
New Delhi: India has developed a powerful new malaria drug — an alternative to the global drug of choice Artemisinin — that promises to be a major boost to India’s pharmaceutical research. The new drug’s
-
Drug Cos told to pay 4,000cr Penalty
Bombay HC refuses to stay 1996 notice to 500 companies on overcharging for bulk drugs More than 500 Indian drug companies will have to collectively pay over . 4,000 crore in dues after a high court shot
-
Ranbaxy to pay US FDA $500m
Mumbai: Japanese drug major Daiichi has lowered its profit forecast for the year ending March 2012, and slashed senior executive pay, to offset the impending loss arising out of its Indian subsidiary,
-
Intrigue in white lab coats
The Lipitor incident provides us with some insight into the pharmaceutical world, where science rubs shoulders with greed and intrigue On Wednesday, Ranbaxy put out an advertisement in the newspapers
-
Ranbaxy launches generic Lipitor
Cholesterol Drug Hits US Stores The Day Pfizer Loses Patent Protection Mumbai: India’s largest drug company, Ranbaxy, which had been chasing a dream for years to launch the first generic version of world’s
-
India may not get a High on World’s Top Drug
Lipitor goes off patent today, but Pfizer may’ve queered pitch for clones, impacting Ranbaxy-led Indian pharma Indian pharma companies’ quest to make millions from the sale of copycat versions of blockbuster
-
FDI Curbs in Pharma Could Deter MNCs: Pfizer India MD
India’s attempts to check foreign investment in pharma and expand drug pricing control could force multinationals to exit the country, the head of Pfizer India has warned. “India might not become attractive
-
Ranbaxy's malaria drug awaits international nod
Even as India’s largest drug maker, Ranbaxy, is confident of launching its first “new drug” by January 2012 to combat malaria in the country, the global euphoria the potential drug had generated in the